雌激素替代治疗与类风湿关节炎患者躯体功能的关系
该纵向研究分析美国Forward数据库2000-22年8246例绝经后类风湿关节炎女性,将4123例雌激素替代治疗(ERT)使用者与非使用者1:1匹配,发现ERT与HAQ评分轻度改善相关(β=-0.02,95%CI -0.03,-0.01;P<0.001),绝经后5年内启动ERT者获益更大,未观察到心血管或癌症事件粗发生率升高。
要点
- ERT与绝经后RA女性HAQ评分轻度改善相关(β=-0.02,95%CI -0.03,-0.01;P<0.001)。
- 绝经后5年内启动ERT者躯体功能获益更大,较晚绝经与更好功能相关。
- 未观察到ERT使用者心血管或癌症事件粗发生率升高。
核心结论
- ERT使用与绝经后RA女性躯体功能及其他患者报告结局轻度改善相关,早期绝经后启动获益最大。
研究设计与样本
- 纵向研究分析Forward国家风湿病数据库2000-22年数据,纳入8246例绝经后RA女性,4123例ERT使用者按绝经年份或ERT启动时间1:1匹配非使用者。
主要发现
- ERT使用与HAQ评分轻度改善相关(β=-0.02,95%CI -0.03,-0.01;P<0.001)。
- 绝经后每增加一年与更好功能相关(β=-0.008,95%CI -0.03,-0.01;P<0.001)。
- 绝经后5年内启动ERT的女性获益更大,倾向评分匹配敏感性分析证实上述发现并显示患者报告结局额外改善。
- 未观察到ERT使用者心血管或癌症事件粗发生率升高。
临床怎么用
- 对绝经后RA女性,尤其是绝经后5年内者,ERT可能作为改善躯体功能的辅助选项,但需个体化评估。
局限性
- 研究为观察性设计,ERT与躯体功能的关联不能推断因果,临床意义尚需进一步研究确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Postmenopausal women with RA experience worsening functional decline, independent of disease activity. Estrogen replacement therapy (ERT) has been proposed to mitigate musculoskeletal deterioration, but its role in RA remains unclear. This study investigated the association between ERT use and physical function in postmenopausal women with RA. METHODS: This longitudinal study analysed data from 'Forward, the National Databank for Rheumatic Diseases' (2000-22). Postmenopausal women with RA who initiated ERT were matched 1:1 to non-users based on menopause year or ERT initiation. The primary outcome was physical function, assessed using the HAQ. Generalized estimating equations (GEE) were used to evaluate the association between ERT and HAQ scores, adjusting for demographics, reproductive history, RA duration, comorbidities and medication use. Sensitivity analyses with propensity score matching were conducted. RESULTS: A total of 8246 women were included, with 4123 ERT users matched to non-users. ERT use was associated with modestly improved HAQ scores (β = -0.02, 95% CI -0.03, -0.01; P < 0.001). Later menopause correlated with better function (β = -0.008 per year after menopause, 95% CI -0.03, -0.01; P < 0.001). Women initiating ERT within 5 years of menopause demonstrated greater benefits. Sensitivity analyses using propensity score adjustment confirmed these findings and revealed additional improvements in patient-reported outcomes. CONCLUSION: ERT use was modestly associated with improved physical function and other patient-reported outcomes in postmenopausal women with RA, with the greatest benefits seen in early postmenopausal initiation. No excess crude rates of cardiovascular or cancer events were observed. Further research is needed to determine the clinical implications of ERT in RA management.
引用
- Mollard E, Pedro S, Michaud K, et al. Estrogen replacement therapy and physical function in rheumatoid arthritis. Rheumatology (Oxford). 2026. PMID: 42032824. doi:10.1093/rheumatology/keag197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。